Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BNBenitec Biopharma Inc. logo

Benitec Biopharma Inc. (BNTC)

NASDAQ Capital Market · Currency in USD
$8.65 ▼ -0.17 (-1.93%)
At close: Oct 23, 4:00 PM ET. Market closed.
$8.79 ▲ +0.14 (+1.62%)
After hours: Oct 23, 4:14 PM ET

Summary

Previous Close
$8.82
Open
$8.83
Day's Range
$8.55 – $8.83
52 Week Range
$8.00 – $16.76
Volume
158,391
Avg. Volume
162,294
Market Cap
$301.74M
Beta (5Y Monthly)
0.25
PE Ratio (TTM)
--
EPS (TTM)
-$0.98
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Jun 1, 2018
1y Target Est
$18.67

Profile: Benitec Biopharma Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
24
CEO
Jerel A. Banks

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.27
DateEst.Actual
Sep 14, 2026-$0.26-$0.26Beat
May 14, 2026-$0.27-$0.24Beat
Feb 12, 2026-$0.23-$0.26Miss
Nov 14, 2025-$0.35-$0.22Beat
Sep 22, 2025-$0.28-$0.42Miss
May 14, 2025-$0.36-$0.24Beat

Analyst view

Consensus price target
$18.67 ▲ +115.8%
Range $14.00 – $25.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on BNTC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.